Financials in USD. Standardized financial statements.
A compact view of how Silence Therapeutics plc turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $559,000 | $43.26M | $25.38M | $17.65M | $12.41M | $5.48M | $244,000 | $0 | $16,000 | $770,000 |
| Revenue Growth? | -98.7% | +70.5% | +43.7% | +42.2% | +126.6% | +2145.5% | 0.0% | -100.0% | -97.9% | 0.0% |
| Cost of Revenue? | $215,000 | $11.81M | $10.32M | $10.97M | $7.46M | $3.76M | $0 | $9.74M | $7.94M | $8.71M |
| Gross Profit? | $344,000 | $31.45M | $15.06M | $6.68M | $4.96M | $1.72M | $244,000 | -$9.74M | -$7.93M | -$7.94M |
| Gross Margin? | +61.5% | +72.7% | +59.3% | +37.8% | +39.9% | +31.3% | +100.0% | 0.0% | -49543.8% | -1031.3% |
| Operating Expenses? | $90.10M | $94.77M | $64.66M | $56.44M | $50.77M | $37.56M | $22.98M | $10.83M | $6.46M | $3.96M |
| Operating Income? | -$89.75M | -$63.32M | -$49.60M | -$49.76M | -$45.81M | -$35.85M | -$22.73M | -$20.57M | -$14.39M | -$11.91M |
| EBITDA? | -$89.20M | -$48.99M | -$49.78M | -$49.27M | -$45.42M | -$35.53M | -$22.36M | -$20.17M | -$3.33M | -$11.60M |
| Income Before Tax | -$88.60M | -$44.46M | -$50.31M | -$40.47M | -$45.86M | -$36.04M | -$22.87M | -$20.53M | -$3.77M | -$10.36M |
| Income Tax Expense | $11,000 | $845,000 | -$7.04M | $560,854 | -$6.45M | -$3.49M | -$3.29M | -$2.12M | -$2.16M | -$1.92M |
| Net Income? | -$88.61M | -$45.31M | -$43.27M | -$41.03M | -$39.41M | -$32.55M | -$19.58M | -$18.41M | -$1.62M | -$8.44M |
| EPS? | $-1.89 | $-2.37 | $-3.48 | $-3.78 | $-1.35 | $-1.11 | $-0.78 | $-0.78 | $-0.07 | $-0.36 |
| Diluted EPS? | $-1.89 | $-2.37 | $-3.48 | $-3.78 | $-1.35 | $-1.11 | $-0.78 | $-0.78 | $-0.07 | $-0.36 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality